Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Proteomedix | ProteoMediX | Proteomedix AG
Related tests:


Results published demonstrating accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. (Proteomedix Press Release)
"Proteomedix...announced that new results evaluating Proclarix® in combination with imaging were published in BJU International...The aim of the study highlighted here was the assessment of the diagnostic performance of Proclarix in combination with mpMRI."
Clinical data
Proteomedix receives IVDR certification for Proclarix. (Proteomedix Press Release)
"Proteomedix...announced that is has received IVDR certification for its prostate cancer diagnostic test Proclarix® from TÜV SÜD...The new In Vitro Diagnostic Regulation (IVDR) recently replaced the IVD Directive. Under the IVDR, diagnostic products are categorized under a new system of one of four classifications from class A (low risk) to class D (highest risk). Proclarix as class C was assessed by TÜV SÜD for conformity resulting in IVDR certification."
Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercialization (Immunovia Press Release)
"Immunovia AB...announced that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer. This will enable increased R&D productivity for Immunovia as the Company continues to strengthen its commercial development in the US...The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics, who have both launched innovative oncology tests, Immunovia with IMMray™ PanCan-d in the U.S. and Proteomedix with Proclarix® in Europe."
Licensing / partnership • Commercial
IMMray™ PanCan-d